Skip to content
AnalystLens

IDEXX Laboratories Quarterly Report for Q3 Ended Sep 30, 2024

Filing Date
Filed October 31, 2024
Period End
September 30, 2024
Security
IDXX
One revenue dollarkept$0.24
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Oct ’19Oct ’19
  2. Material agreement8-K · Dec ’21Dec ’21
  3. Leadership change8-K · Mar ’26Mar ’26

Summary

Summary of the 10-Q filed October 31, 2024. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories, Inc. reported strong third-quarter results, demonstrating robust revenue growth driven by its core Companion Animal Group (CAG) segment.

Total revenue increased by 6.6% year-over-year to $975.5 milliona, with organic revenue growing by 6.1%, highlighting the company's ability to drive growth through a combination of price realization and volume increases across its diagnostic consumables and services. The company maintained healthy profitability, with gross profit margin improving to 61.1% and operating income rising by 10.4% to $303.9 million.

This financial performance was supported by effective cost management and favorable business mix, despite ongoing inflationary pressures. IDEXX also continues to execute its capital allocation strategy, with significant share repurchases and investments in growth, while maintaining a strong liquidity position and compliance with financial covenants.

Key Highlights

  1. Total revenue for the third quarter increased by 6.6% to $975.5 million, driven by a 6.1% organic revenue growth.
  2. The Companion Animal Group (CAG) segment continues to be the primary growth driver, with revenue up 6.5% to $892.0 million, fueled by recurring diagnostics and software services.
  3. Gross profit margin improved to 61.1% from 59.9% in the prior year, reflecting favorable business mix, pricing power, and cost management.
  4. Operating income saw a significant increase of 10.4% to $303.9 million.
  5. The company maintained a strong liquidity position, with cash and cash equivalents of $308.6 million and an available borrowing capacity of $998.2 million under its credit facility.
  6. Significant share repurchases were executed, with $225.2 million spent in the third quarter and $610.7 million year-to-date, demonstrating a commitment to returning capital to shareholders.
  7. The company announced an increase in its accrual for an ongoing litigation matter to $89.0 million, which impacted general and administrative expenses but did not derail overall operational performance.

Follow one dollar

Of each $1.00 of revenue in Q3 FY2024, IDEXX Laboratories kept $0.24.

  1. Revenue$975.5M100.0%
  2. Cost of revenue−$379.5M38.9%
  3. Gross profit$596.0M61.1%
  4. Operating costs−$292.1M29.9%
  5. Operating income$303.9M31.2%
  6. Interest, other & tax−$71.1M7.3%
  7. Net income$232.8M23.9%
Computed from 10-QQ3 FY2024filed October 31, 2024Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q3 FY2024 against Q3 FY2023

Line itemQ3 FY2024Q3 FY2023Change
Revenue$975.54M$915.53M+6.6%
Cost of Revenue$379.50M$367.55M+3.3%
Gross Profit$596.04M$547.98M+8.8%
R&D Expenses$53.98M$47.97M+12.5%
Operating Expenses$292.15M——
Operating Income$303.89M$275.28M+10.4%
Net Income$232.84M$212.23M+9.7%
EPS (Basic)$2.83$2.55+11.0%
EPS (Diluted)$2.80$2.53+10.7%
Shares Outstanding (Basic)82.30M83.10M−1.0%
Shares Outstanding (Diluted)83.06M83.99M−1.1%

Frequently Asked Questions

  1. What were the main drivers of revenue growth in the third quarter?

    Revenue growth was primarily driven by increases in the Companion Animal Group (CAG) segment, specifically from recurring diagnostic revenue (up 6.7%), IDEXX VetLab consumables (up 11.2%), and veterinary software and services (up 11.4%). This growth was supported by higher realized prices, increased volumes, new business gains, and high customer retention rates.

  2. How did the company manage costs and profitability amidst inflationary pressures?

    IDEXX demonstrated effective cost management, leading to an improved gross profit margin of 61.1%. This was achieved through a favorable business mix, lower instrument costs, recurring software and services gross margin gains, and net price realization, which helped offset inflationary cost impacts on labor, commodities, and transportation.

  3. What is the company's capital allocation strategy, and how is it being executed?

    The company continues to actively repurchase its common stock, with $225.2 million spent in the third quarter and $610.7 million year-to-date, demonstrating a commitment to returning capital to shareholders and offsetting the dilutive effects of share-based compensation. IDEXX also invests in growth initiatives and maintains a strong liquidity position to support its operations and future opportunities.

  4. Are there any significant legal or contingent liabilities that investors should be aware of?

    The company increased its accrual for an ongoing litigation matter concerning alleged underpayment of royalty payments to $89.0 million. While this impacted operating expenses, the company continues to defend itself. Management believes that aside from this matter, other pending legal actions are not expected to have a material adverse effect on the company's financial condition or results of operations.